Q1 2026 · 13F-HR/A
Avidity Partners Management LPholdings as filed
Filed 2026-05-28 · accession 0001791827-26-000004
$493.8M
Reported value
45
Positions
2026-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $176.6M | 35.8% | 2,104,184 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $87.2M | 17.7% | 1,288,948 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $37.3M | 7.55% | 760,424 | Common | SOLE |
| 46489V302 | CATX | PERSPECTIVE THERAPEUTICS INC | $25.2M | 5.11% | 6,049,999 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $19.7M | 3.99% | 1,400,708 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $15.7M | 3.18% | 400,000 | Common | SOLE |
| 881624209 | TEVA | TEVA PHARM ADR | $13.6M | 2.75% | 450,100 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $13.1M | 2.65% | 4,998,267 | Common | SOLE |
| 759916109 | RGEN | REPLIGEN CORP | $9.2M | 1.86% | 77,800 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC | $8.7M | 1.77% | 70,000 | Common | SOLE |
| G5960L103 | MDT | MEDTRONIC INC | $8.7M | 1.75% | 100,000 | Common | SOLE |
| 92764N102 | VIR | VIR BIOTECHNOLOGY INC | $8.5M | 1.72% | 950,000 | Common | SOLE |
| 01021M104 | AKTS | AKTIS ONCOLOGY INC | $8.4M | 1.70% | 468,566 | Common | SOLE |
| 4525EP101 | VTLUSD | IMMUNIC INC | $7.4M | 1.51% | 6,699,411 | Common | SOLE |
| 252131107 | DXCM | DEXCOM | $5.7M | 1.14% | 90,000 | Common | SOLE |
| 29261A100 | EHC | ENCOMPASS HEALTH CORP | $4.1M | 0.82% | 42,000 | Common | SOLE |
| 101137107 | BSX | BOSTON SCIENTIFIC CORPORATION | $3.8M | 0.76% | 60,000 | Common | SOLE |
| 88032L605 | TENX | TENAX THERAPEUTICS INC | $3.5M | 0.70% | 215,934 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $2.8M | 0.56% | 20,000 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $2.8M | 0.56% | 249,390 | Common | SOLE |
| 48576U205 | KPTI | KARYOPHARM THERAPEUTICS INC | $2.6M | 0.52% | 463,741 | Common | SOLE |
| 15135B101 | CNC | CENTENE CORP | $2.3M | 0.46% | 70,000 | Common | SOLE |
| 80401L803 | MSLE | SATELLOS BIOSCIENCE INC | $2.2M | 0.44% | 387,769 | Common | SOLE |
| 811292200 | SCYX | SCYNEXIS INC | $1.9M | 0.39% | 2,081,660 | Common | SOLE |
| 632307104 | NTRA | NATERA INC | $1.8M | 0.36% | 9,000 | Common | SOLE |
| G4705A100 | ICLR | ICON PLC | $1.8M | 0.36% | 16,000 | Common | SOLE |
| 49177J102 | KVUE | KENVUE INC ORD | $1.7M | 0.35% | 100,000 | Common | SOLE |
| 221015100 | CRVS | CORVUS PHARMACEUTICALS INC | $1.7M | 0.34% | 115,000 | Common | SOLE |
| 433000106 | HIMS | HIMS & HERS HEALTH INC | $1.6M | 0.32% | 75,000 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $1.5M | 0.30% | 15,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $1.4M | 0.29% | 30,000 | Common | SOLE |
| 372303206 | GMAB | GENMAB A/S -SP ADR | $1.3M | 0.27% | 50,000 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERA | $1.2M | 0.24% | 30,000 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $1.1M | 0.23% | 25,000 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA-ADR | $1.1M | 0.23% | 10,000 | Common | SOLE |
| 91324P102 | UNH | UNITEDHEALTH GRP | $1.0M | 0.21% | 3,800 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $961,500 | 0.19% | 75,000 | Common | SOLE |
| M7518J104 | ODD | ODDITY TECH LTD-CL A | $936,600 | 0.19% | 70,000 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $932,000 | 0.19% | 50,000 | Common | SOLE |
| 70614W100 | PTON | PELOTON INTERACTIVE INC-A | $858,000 | 0.17% | 200,000 | Common | SOLE |
| 03675P102 | AVR | ANTERIS TECHNOLOGIES GLOBAL | $832,500 | 0.17% | 150,000 | Common | SOLE |
| 03879J100 | ABUS | ARBUTUS BIOPHARMA CORP | $562,500 | 0.11% | 125,000 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUTIC | $392,484 | 0.08% | 43,853 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARM | $288,645 | 0.06% | 12,967 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $79,454 | 0.02% | 6,660 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.